Day: March 20, 2021

Core One Labs Files Application to List its Common Shares on NASDAQ

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, March 20, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One” or the “Company”) is pleased to announce that it has filed an application to list its common shares on the Capital Market tier of The NASDAQ Stock Market LLC (“Nasdaq”). Nasdaq is ranked as the second-largest exchange by market capitalization in the world and Core One expects the listing to increase both investor awareness generally and market liquidity for the Company’s current and future shareholders. The listing of Core One’s shares on Nasdaq is subject to the Company’s satisfaction of a number of conditions, including registration of Core One’s common shares with the U.S. Securities and Exchange Commission (the “SEC”) and a determination by the Nasdaq Listing Qualifications Staff...

Continue reading

Cameco annonce le dépôt de son rapport annuel

Written by Customer Service on . Posted in Public Companies.

SASKATOON (Saskatchewan), 20 mars 2021 (GLOBE NEWSWIRE) — Cameco (TSX : CCO; NYSE : CCJ) a annoncé aujourd’hui le dépôt de son rapport annuel auprès de la Securities and Exchange Commission des États-Unis via le formulaire 40-F. Ce document inclut les états financiers annuels vérifiés de Cameco pour l’exercice achevé le 31 décembre 2020, son rapport de gestion et sa notice annuelle canadienne. De plus, Cameco a déposé sa notice annuelle auprès des Autorités canadiennes en valeurs mobilières. Les états financiers annuels vérifiés pour l’exercice achevé le 31 décembre 2020 et le rapport de gestion ont été déposés auprès des Autorités canadiennes en valeurs mobilières en février 2021. Tous ces documents sont disponibles sur notre site Web. Les actionnaires peuvent obtenir gratuitement des copies papier de ces documents,...

Continue reading

Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021

Written by Customer Service on . Posted in Public Companies.

— Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy — — Additional poster presentations include Phase 3 data in Bardet-Biedl and Alström syndromes and analyses of adverse events in Phase 2 and Phase 3 studies in POMC, PCSK1, or LEPR deficiency showing consistent safety results for setmelanotide — BOSTON, March 20, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that three late-breaking data presentations from Phase 2 and Phase 3 studies of setmelanotide were presented during the 103rd Annual Meeting and Expo of the Endocrine Society (ENDO 2021) held virtually March 20-23. Sadaf...

Continue reading

89bio Presents Additional Analysis of Phase 1b/2a NASH Study at the Annual ENDO 2021 Conference

Written by Customer Service on . Posted in Public Companies.

SAN FRANCISCO, March 20, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional positive data from its Phase 1b/2a study of BIO89-100, a long-acting glycoPEGylated FGF21 analog, in patients with nonalcoholic steatohepatitis (NASH). The data will be presented in an on-demand poster presentation at ENDO 2021, the Endocrine Society’s annual meeting taking place virtually from March 20-23, 2021. “Excess liver fat is an important driver of disease progression for people living with NASH and can be associated with increased risk for cardiovascular events and even death,” said Hank Mansbach, chief medical officer of 89bio. “We are encouraged...

Continue reading

Theratechnologies Announces New Data Demonstrating Tesamorelin’s Positive Effect on Immune Response Linked to Liver Inflammation

Written by Customer Service on . Posted in Public Companies.

MONTREAL, March 20, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new data, demonstrating the positive effect of tesamorelin on the circulation of immune activation markers associated with liver inflammation, was presented today at The Endocrine Society’s annual meeting, ENDO 2021. Dr. Takara L. Stanley, Assistant Professor of Pediatrics, Harvard Medical School, Assistant Pediatrician, Massachusetts General Hospital and Program Director, Pediatric Endocrine Fellowship Program, MGHfC, authored the poster presented at ENDO 2021. The data comes from a sub-analysis of a double-blind, randomized, 12-month investigator-initiated trial studying the effect of tesamorelin...

Continue reading

Theratechnologies annonce de nouvelles données démontrant l’effet positif de la tésamoréline sur la réponse immunitaire liée à l’inflammation du foie

Written by Customer Service on . Posted in Public Companies.

MONTRÉAL, 20 mars 2021 (GLOBE NEWSWIRE) — Theratechnologies inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), une société biopharmaceutique commerciale axée sur le développement et la commercialisation de traitements innovateurs, a le plaisir d’annoncer que de nouvelles données, démontrant l’effet positif de la tésamoréline sur la circulation des marqueurs d’activation immunitaire associés à l’inflammation du foie, ont été présentées aujourd’hui à la réunion annuelle de l’Endocrine Society, ENDO 2021. Dr Takara L. Stanley, professeur adjoint en pédiatrie, au Harvard Medical School, assistant pédiatre au Massachusetts General Hospital, et directeur de programme du Pediatric Endocrine Fellowship Program au MGHfC, a été l’auteur du poster présenté à ENDO 2021. Les données sont tirées de la sous-analyse d’un essai de 12 mois à double...

Continue reading

BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting

Written by Customer Service on . Posted in Public Companies.

– Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept – At Doses up to 180 mg Twice Daily, Encaleret was Well-Tolerated with No Serious Adverse Events and No Adverse Events of Moderate or Severe Intensity Reported After 5 Days – Company to Host Webcast to Discuss Data on March 22 at 8:00 a.m. ET PALO ALTO, Calif., March 20, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced early results from an ongoing Phase 2b proof-of-concept, open-label study of encaleret for the treatment of Autosomal...

Continue reading

Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021

Written by Customer Service on . Posted in Public Companies.

–Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)– –Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching from iSRLs– NEEDHAM, Mass., March 20, 2021 (GLOBE NEWSWIRE) — Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent phased launch of MYCAPSSA® as the first oral therapy for the treatment of acromegaly, today announced the presentation of new positive clinical data from its MPOWERED™ Phase...

Continue reading

Strongbridge Biopharma plc Presents Detailed Results from Pivotal Phase 3 LOGICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2021 Annual Meeting of the Endocrine Society (ENDO)

Written by Customer Service on . Posted in Public Companies.

~ As Previously Reported, LOGICS Met its Primary Endpoint with Statistical Significance ~ ~ Strongbridge Recently Submitted a New Drug Application (NDA) forRECORLEV® (levoketoconazole) to the U.S. Food & Drug Administration ~ DUBLIN, Ireland and TREVOSE, Pa., March 20, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that detailed results from the previously reported Phase 3 LOGICS study of RECORLEV® (levoketoconazole) in patients with endogenous Cushing’s syndrome were presented in a poster session at the Annual Meeting of the Endocrine Society (ENDO), being held virtually from March 20 – 23, 2021. “We are pleased to share...

Continue reading

Data Presented at ENDO 2021 Differentiate LUM-201 from Standard Growth Hormone Secretagogues and Further Support LUM-201’s Potential as a Therapeutic for Pediatric Growth Hormone Deficiency

Written by Customer Service on . Posted in Public Companies.

AUSTIN, Texas, March 20, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the poster 7102 entitled, “LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency,” is being presented by authors Bright, G., et al in Poster Session 33 at ENDO 2021, the Endocrine Society’s Annual Meeting, taking place virtually from March 20-23, 2021. The poster can be viewed on the ENDO website and may also be found on the Company’s website in the Investors & Media section, under “Posters & Publications.” “These data presented today at the Endocrine Society Annual Meeting illustrate LUM-201’s unique ability to stimulate peak GH levels significantly higher than those produced by standard...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.